First-in-human Phase i study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Androgen Antagonists
  • DNA
  • Prostatic Neoplasms
  • Receptors, Androgen

abstract

  • Activity of EZN-4176 at the doses and schedules explored was minimal. The highest dose of 10 mg kg(-1) QW was associated with significant but reversible transaminase elevation.

publication date

  • November 12, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3833213

Digital Object Identifier (DOI)

  • 10.1038/bjc.2013.619

PubMed ID

  • 24169353

Additional Document Info

start page

  • 2579

end page

  • 86

volume

  • 109

number

  • 10